3月24日 - ** 药物开发商 Entrada Therapeutics 的 TRDA.O 股价上涨 2.5% 至 10.75 美元
** 该公司表示， (link)，它已获得英国监管机构的授权，开始对一种实验性药物ENTR-601-45进行早期研究，该药物可能用于治疗杜氏肌营养不良症（一种肌肉萎缩性疾病）。
** Entrada公司称有望在2025年第三季度开始研究
** 公司股价在过去12个月中下跌了22.5%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.